IQVIA Holdings Inc. $IQV Stake Raised by OVERSEA CHINESE BANKING Corp Ltd

OVERSEA CHINESE BANKING Corp Ltd grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 29.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,037 shares of the medical research company’s stock after buying an additional 2,941 shares during the period. OVERSEA CHINESE BANKING Corp Ltd’s holdings in IQVIA were worth $2,939,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Ameliora Wealth Management Ltd. bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $25,000. Physician Wealth Advisors Inc. raised its holdings in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the last quarter. Westside Investment Management Inc. raised its holdings in shares of IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new stake in shares of IQVIA during the third quarter valued at approximately $30,000. Finally, Atlantic Union Bankshares Corp bought a new stake in shares of IQVIA during the third quarter valued at approximately $36,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.2%

IQVIA stock opened at $175.34 on Thursday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market cap of $29.76 billion, a price-to-earnings ratio of 22.31, a price-to-earnings-growth ratio of 1.75 and a beta of 1.39. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The firm’s 50 day moving average price is $170.28 and its two-hundred day moving average price is $203.30.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on IQV shares. Citigroup lowered their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. UBS Group lowered their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday. Finally, Mizuho set a $215.00 price objective on shares of IQVIA in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $226.63.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.